These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 6475981)

  • 1. 24-hour mean pulse. Simple predictor of doxorubicin-induced cardiac damage.
    Hrushesky WJ; Vukelich M; Steiner B; Dell I; Mukai K
    Am J Med; 1984 Sep; 77(3):399-406. PubMed ID: 6475981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circadian mesor of recumbent pulse--cost-effective predictor of doxorubicin-induced congestive heart failure.
    Hrushesky WJ; Vukelich M
    Chronobiol Int; 1984; 1(1):59-66. PubMed ID: 6600010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
    Schwartz RG; McKenzie WB; Alexander J; Sager P; D'Souza A; Manatunga A; Schwartz PE; Berger HJ; Setaro J; Surkin L
    Am J Med; 1987 Jun; 82(6):1109-18. PubMed ID: 3605130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.
    Speyer JL; Green MD; Dubin N; Blum RH; Wernz JC; Roses D; Sanger J; Muggia FM
    Am J Med; 1985 Apr; 78(4):555-63. PubMed ID: 3838618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early and delayed clinical cardiotoxicity of doxorubicin.
    Buzdar AU; Marcus C; Smith TL; Blumenschein GR
    Cancer; 1985 Jun; 55(12):2761-5. PubMed ID: 3922612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cardiotoxicity of adriamycin and daunomycin in children.
    Gilladoga AC; Manuel C; Tan CT; Wollner N; Sternberg SS; Murphy ML
    Cancer; 1976 Feb; 37(2 Suppl):1070-8. PubMed ID: 1253124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive monitoring of adriamycin cardiotoxicity by "Sphygmo-Recording" of the pulse wave delay (QKd interval).
    Greco FA; Brereton HD; Rodbard D
    Cancer Treat Rep; 1976 Sep; 60(9):1239-45. PubMed ID: 797446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience.
    Ibrahim NK; Hortobagyi GN; Ewer M; Ali MK; Asmar L; Theriault RL; Fraschini G; Frye DK; Buzdar AU
    Cancer Chemother Pharmacol; 1999; 43(6):471-8. PubMed ID: 10321507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
    Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
    J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
    Speyer JL; Green MD; Zeleniuch-Jacquotte A; Wernz JC; Rey M; Sanger J; Kramer E; Ferrans V; Hochster H; Meyers M
    J Clin Oncol; 1992 Jan; 10(1):117-27. PubMed ID: 1727913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
    Giordano SH; Booser DJ; Murray JL; Ibrahim NK; Rahman ZU; Valero V; Theriault RL; Rosales MF; Rivera E; Frye D; Ewer M; Ordonez NG; Buzdar AU; Hortobagyi GN
    Clin Cancer Res; 2002 Nov; 8(11):3360-8. PubMed ID: 12429622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
    Lipshultz SE; Colan SD; Gelber RD; Perez-Atayde AR; Sallan SE; Sanders SP
    N Engl J Med; 1991 Mar; 324(12):808-15. PubMed ID: 1997853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
    Skubitz KM; Blaes AH; Konety SH; Francis GS
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance.
    Choi BW; Berger HJ; Schwartz PE; Alexander J; Wackers FJ; Gottschalk A; Zaret BL
    Am Heart J; 1983 Oct; 106(4 Pt 1):638-43. PubMed ID: 6613807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial studies of cardiac function in patients receiving adriamycin.
    Henderson IC; Sloss LJ; Jaffe N; Blum RH; Frei E
    Cancer Treat Rep; 1978 Jun; 62(6):923-9. PubMed ID: 667869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin-induced congestive heart failure in adults.
    Haq MM; Legha SS; Choksi J; Hortobagyi GN; Benjamin RS; Ewer M; Ali M
    Cancer; 1985 Sep; 56(6):1361-5. PubMed ID: 4027874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for doxorubicin-induced congestive heart failure.
    Von Hoff DD; Layard MW; Basa P; Davis HL; Von Hoff AL; Rozencweig M; Muggia FM
    Ann Intern Med; 1979 Nov; 91(5):710-7. PubMed ID: 496103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients.
    Shapiro CL; Hardenbergh PH; Gelman R; Blanks D; Hauptman P; Recht A; Hayes DF; Harris J; Henderson IC
    J Clin Oncol; 1998 Nov; 16(11):3493-501. PubMed ID: 9817266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas.
    Dresdale A; Bonow RO; Wesley R; Palmeri ST; Barr L; Mathison D; D'Angelo T; Rosenberg SA
    Cancer; 1983 Jul; 52(1):51-60. PubMed ID: 6850545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.